Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease — THRIVE

cGVHD Clinical Trial

Official title:
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Status Recruiting

Clinical Trial Summary

The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Bronchiolitis Obliterans Syndrome
cGVHD
Graft vs Host Disease

Clinical Trial Details

NCT number	NCT05919511
Study type	Observational
Source	Incyte Corporation
Contact	Incyte Corporation Call Center (US)
Phone	1.855.463.3463
Email	medinfo@incyte.com
Status	Recruiting
Phase
Start date	August 2, 2023
Completion date	October 15, 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01221766` - Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease	N/A
Recruiting	`NCT06186804` - A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)	Phase 2
Not yet recruiting	`NCT06458127` - Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease	N/A
Recruiting	`NCT06244628` - Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD	Phase 3
Withdrawn	`NCT05604742` - Belimumab for Treatment of cGVHD Following Allo-HCT	Phase 1/Phase 2
Recruiting	`NCT05214066` - Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT	Phase 2
Not yet recruiting	`NCT06364319` - Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD	Phase 4